This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer CI
The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California CI
Transcript : The Oncology Institute, Inc., Q4 2023 Earnings Call, Mar 27, 2024
The Oncology Institute Q4 Loss Widens, Revenue Increases MT
(TOI) THE ONCOLOGY INSTITUTE Forecasts Fiscal Year 2024 Revenue Range $400M - $415M MT
Earnings Flash (TOI) THE ONCOLOGY INSTITUTE Posts Q4 Revenue $85.8M MT
The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2024 CI
The Oncology Institute, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
MaxHealth & The Oncology Institute, Inc. Expand Value-Based Care Partnership CI
The Oncology Institute Expands Its Specialty Medication Business by Opening Pharmacy Operations in California CI
Oncology Institute Insider Sold Shares Worth $118,581, According to a Recent SEC Filing MT
Transcript : The Oncology Institute, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Tranche Update on The Oncology Institute, Inc.'s Equity Buyback Plan announced on August 30, 2023. CI
Tranche Update on The Oncology Institute, Inc.'s Equity Buyback Plan announced on June 15, 2023. CI
The Oncology Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (TOI) TOI MANAGEMENT LLC Reports Q3 Revenue $82M, vs. Street Est of $74.7M MT
The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Year 2023 CI
The Oncology Institute Reports Goodwill Impairment Charge for the Nine Months Ended 2023 CI
The Oncology Institute, Inc. Names Jeremy Castle as Chief Operations Officer CI
The Oncology Institute Appoints Jeremy Castle as Chief Operations Officer MT
The Oncology Institute Regains Compliance With Nasdaq's Minimum Closing Bid Price Rule MT
The Oncology Institute, Inc. Appoints Jeremy N. Castle as Chief Operations Officer CI
The Oncology Institute, Inc. Announces Resignation of Ravi Sarin as Member of the Board of Directors and Committees CI
Oncology Institute to Buy Back 2 Million Shares DJ
The Oncology Institute, Inc. announces an Equity Buyback for 2,000,000 shares, for $2 million. CI
Chart The Oncology Institute, Inc.
More charts
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.13 USD
Average target price
2.5 USD
Spread / Average Target
+121.24%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. TOI Stock
  4. News The Oncology Institute, Inc.
  5. Guggenheim Adjusts Price Target on The Oncology Institute to $6 From $7, Maintains Buy Rating